

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 11, 2021

Reference is made to the circular (the “**Circular**”) and the notice of the annual general meeting (the “**AGM**”) (the “**AGM Notice**”) of Alphamab Oncology (the “**Company**”) both dated April 28, 2021. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular and AGM Notice.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that at the AGM held on June 11, 2021, all proposed resolutions as set out in the AGM Notice were duly approved by the Shareholders by way of poll.

As at the date of the AGM, the total number of issued shares of the Company was 935,836,620 shares. No Shareholders were required under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) to abstain from voting on any of the resolutions at the AGM and no Shareholders were entitled to attend and abstain from voting in favor as set out in Rule 13.40 of the Listing Rules. No Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM.

The Company’s share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

The poll results in respect of each resolution proposed at the AGM were as follow:

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
1.	To consider and receive the audited consolidated financial statements of the Company and the reports of the Directors and the auditors of the Company for the year ended December 31, 2020	174,261,012 100.000000%	0 0.000000%
2.	To grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company	174,261,012 100.000000%	0 0.000000%
3.	To grant a general mandate to the Directors to allot, issue and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company	98,355,714 56.441606%	75,905,298 43.558394%
4.	To extend the general mandate granted to the Directors to issue shares of the Company by adding thereto the shares to be bought back by the Company	106,601,412 61.173415%	67,659,600 38.826585%
5.	(i) To re-elect Ms. LIU Yang as an executive Director	137,958,314 79.167630%	36,302,698 20.832370%
	(ii) To re-elect Mr. WEI Kevin Cheng as an independent non-executive Director	172,905,012 99.221857%	1,356,000 0.778143%
	(iii) To re-elect Mr. WU Dong as an independent non-executive Director	173,870,012 99.775624%	391,000 0.224376%
6.	To authorize the Board to fix the remuneration of the Directors	174,261,012 100.000000%	0 0.000000%
7.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors of the Company and authorize the Board to fix their remuneration	174,261,012 100.000000%	0 0.000000%

Note: The full text of the above resolutions are set out in the AGM Notice.

As more than 50% of votes were cast in favour of the ordinary resolutions nos. 1 to 7 above, all such resolutions were duly passed by the Shareholders as ordinary resolutions.

By order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, June 11, 2021

As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin and Mr. QIU Yu Min as Non-executive Directors, and Dr. JIANG Hualiang, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.